Optimizing the science of drug development: Opportunities for better candidate selection and accelerated evaluation in humans

European Journal of Pharmaceutical Sciences

Volumn 10, Issue 4, 2000, Pages

  Lesko, Lawrence J ^a   Rowland, Malcolm ^b   Peck, Carl C ^c   Blaschke, Terrence F ^d  

^a Off Clin Pharmacol Biopharmaceut   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c GEORGETOWN UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DRUG ANALYSIS; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACOLOGY, CLINICAL;

EID: 0034029795     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(00)00092-0     Document Type: Conference Paper

References (11)

1. Atkinson, A.J., Colburn, W.A., DeGruttola, V., DeMets, D.L., Downing, G.J., Hoth, D.F., Oates, J.A., Peck, C.C., Schooley, R.T., Spilker, B.A., Woodcock, J., Zeger, S.L., submitted. Biomarkers and surrogate endpoints in clinical trials: preferred definitions and conceptual framework. J. Am. Med. Ass.
2. Bruno R., Hille D., Riva A., Vivier N., ten Bokkel Huinnink W.W., van Oosterom A.T., Kaye S.B., Verweij J., Fossella F.V., Valero V., Rigas J.R., Seidman A.D., Chevallier B., Fumoleau P., Burris H.A., Ravdin P.M., Sheiner L.B. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16:1998;187-196.
3. Collins J.M., Grieshaber C.K., Chabner B.A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82:1990;1321-1326.
4. Egan T.D., Lemmens H.J., Fiset P., Hermann D.J., Muir K.T., Stanski D.R., Shafer S.L. The pharmacokinetics of the new short-acting opioid remifentanil (GI 87084B) in healthy adult male volunteers. Anesthesiology. 79:1993;881-892.
5. Glass P.S., Hardman D., Kamiyama Y., Quill T.J., Marton G., Donn K.H., Grosse C.M., Hermann D. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth. Analg. 77:1993;1031-1040.
6. Holford N.H.G., Kimko H.C., Monteleone J.P.R., Peck C.C. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40:2000;209-234.
7. Peck C.C., Barr W.H., Benet L.Z., Collins J., Desjardins R.E., Furst D.E., Harter J.G., Levy G., Ludden T., Rodman J.H., et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin. Pharmacol. Ther. 51:1992;465-473.
8. Reigner B.G., Williams P.E., Patel I.H., Steimer J.L., Peck C., van Brummelen P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin. Pharmacokinet. 33:1997;142-152.
9. Shafer S.L., Varvel J.R. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology. 74:1991;53-63.
10. Sheiner L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61:1997;275-291.
11. Sheiner L.B., Steimer J.-L. Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. Annu. Rev. Pharmacol. Toxicol. 40:2000;67-95.